Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Blood (2012) 120 (8): 1589–1596.

https://doi.org/10.1182/blood-2012-02-408922

Published: 2012

Includes: Supplemental data

Journal Articles

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Blood (2011) 118 (21): 3951.

https://doi.org/10.1182/blood.V118.21.3951.3951

Published: 2011

Journal Articles

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Blood (2011) 118 (3): 529–534.

https://doi.org/10.1182/blood-2011-01-332320

Published: 2011

Journal Articles

Vascular Endothelial Growth Factor (VEGF) Expression by Neoplastic Hodgkin-Reed-Sternberg Cells Is An Independent Adverse Prognostic Factor for Relapse in Hodgkin Lymphoma.

Antonio Gutierrez, MD, Francisco Mestre, Rafael Ramos, Jordi Martinez-Serra, Antonia Bautista, José Fuster, Pilar Lopez-Marti, Marta Casasus, Cristina Nicolau, Julio Rifa, Joan Besalduch, Juan Fernando Garcia, Jose Rodriguez

Blood (2009) 114 (22): 1561.

https://doi.org/10.1182/blood.V114.22.1561.1561

Published: 2009

Journal Articles

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Blood (2009) 114 (22): 4711.

https://doi.org/10.1182/blood.V114.22.4711.4711

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol – A Prospective Clinical Trial by the Grupo Español de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats L Brune, Jakob R. Passweg, Joan Besalduch, Rafael F Duarte, Angel Leon, Maria Jesus Pascual, Norbert Schmitz

Blood (2009) 114 (22): 658.

https://doi.org/10.1182/blood.V114.22.658.658

Published: 2009

Journal Articles

NK and T-Cell Status as Well as Their Perforin Expression Is Related to Clinical Severity and Outcome in Difuse Large Cell Lymphoma.

Antonio Gutierrez, MD, Jose Rodriguez, MD, Jordi Martinez, PhD, Carmen Ballester, MD, Catalina Crespi, PhD, Maria Dolores Bea, LT, Juan Carlos Amat, LT, Roberto Villavicencio, LT, Miguel Morey, MD, Maria Antonia Duran, MD, Cristina Linares, MD, Julio Rifa, MD, Antonia Bautista, MD, Oliver Voegler, PhD, Regina Alemany, PhD, Antonia Sampol, MD, Joan Besalduch, MD

Blood (2007) 110 (11): 1574.

https://doi.org/10.1182/blood.V110.11.1574.1574

Published: 2007

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

Journal Articles

Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.

Blood (2007) 110 (11): 729.

https://doi.org/10.1182/blood.V110.11.729.729

Published: 2007

Journal Articles

Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.

Francesc Bosch, MD, Ana Muntañola, MD, Ana Ferrer, MD, Marcos González, MD, Eva Gine, MD, Eugenia Abella, MD, Santi Gardella, MD, Javier Briones, MD, Eva González-Barca, MD, Lourdes Escoda, MD, Elena Pérez-Ceballos, MD, Antoni Asensi, MD, Maria José Sayas, MD, Joan Besalduch, MD, Emili Montserrat, MD

Blood (2006) 108 (11): 2835.

https://doi.org/10.1182/blood.V108.11.2835.2835

Published: 2006

Journal Articles

Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML).

Blood (2005) 106 (11): 1855.

https://doi.org/10.1182/blood.V106.11.1855.1855

Published: 2005

Journal Articles

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Josep-Maria Ribera, MD, Albert Oriol, MD, Concepcion Bethencourt, MD, Ricardo Parody, MD, Jesus-Maria Hernandez-Rivas, MD, Maria-Jose Moreno, MD, Eloy Del Potro, MD, Mar Tormo, MD, Concepcion Rivas, MD, Joan Besalduch, MD, Miguel-Angel Sanz, MD, Jesus Arias, MD, Javier Fernandez-Calvo, MD, Jose-Maria Moraleda, MD, Javier Bueno, MD, Evarist Feliu, MD, Juan-Jose Ortega, MD

Blood (2004) 104 (11): 2731.

https://doi.org/10.1182/blood.V104.11.2731.2731

Published: 2004

NARROW

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Vascular Endothelial Growth Factor (VEGF) Expression by Neoplastic Hodgkin-Reed-Sternberg Cells Is An Independent Adverse Prognostic Factor for Relapse in Hodgkin Lymphoma.

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

NK and T-Cell Status as Well as Their Perforin Expression Is Related to Clinical Severity and Outcome in Difuse Large Cell Lymphoma.

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.

Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML).

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only